Inocras Inc.

Inocras Inc. is a bioinformatics-led company that leverages whole genome data and proprietary analytics to provide curated insights for precision health. Founded in 2020 by a team of physician-scientists, geneticists, and bioinformaticians, the company's mission is to deliver clear, clinically actionable, whole genome-powered insights for patient care and to build a global-scale bioinformatics platform. Headquartered in San Diego, California, Inocras also maintains offices in Seoul, South Korea, and Hong Kong.

Inocras offers a suite of whole genome diagnostic products, including CancerVision for solid tumor profiling, RareVision for rare disease diagnosis, and MRDVision for molecular residual disease detection. Beyond diagnostic testing, the company provides genetic counseling support and clinical trial matching services for patients. For healthcare providers and researchers, Inocras offers precision DNA sequencing, curation, and interpretation services through its CLIA-certified and CAP-accredited laboratory.

Formerly known as Genome Insight, the company rebranded to Inocras in March 2024. In August 2026, Inocras closed a $31 million Series B-3 financing round, bringing its total funding to approximately $100 million. Led by CEO Jehee Suh, Inocras is actively pursuing an initial public offering (IPO) on the Kosdaq in South Korea. The company has established a significant commercial presence in Asia, supporting over 100 cancer institutions and approximately 30 hospitals in South Korea, and is expanding its operations into the United States.